Drugs / DSM265
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03637517 | Oct → Nov 2018 | — | Medicines for Malaria Venture | Completed | Mixed |
| Phase 1 | NCT02750384 | May → Jul 2016 | — | Medicines for Malaria Venture | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02562872 | Mar 2016 → May 2017 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02450578 | Oct 2015 → Apr 2016 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02573857 | Oct 2015 → May 2016 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded |
| Phase 1/2 | NCT02389348 | Feb → Jun 2015 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02123290 | Jan 2016 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Medicines for Malaria Venture | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSM265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02562872 ↗ |
| Action | Inhibit | “DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH)” PMID 29909069 ↗ Jun 2018 |
| Modality | Small molecule | — CHEMBL1956285 ↗ |
| Route | Oral | “Two initial cohorts received single oral doses of 400 mg DSM265” PMID 29909069 ↗ Jun 2018 |
| Target | DHODH | “the gene encoding the DSM265 target DHODH” PMID 29909069 ↗ Jun 2018 |